Chlorotrianisene
(Synonyms: 氯丁烯二烯) 目录号 : GC10012
A synthetic non-steroidal estrogen
Cas No.:569-57-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Description:
ED50: 2.0 μM
Glandular kallikrein, a trypsin-like serine protease, has been identified as a major estrogen-induced protein in the rat anterior pituitary. This induction appears to be mediated by increased gene expression since glandular kallikrein mRNA is also estrogen-induced. Chlorotrianisene is classified as an estrogen agonist.
In vitro: The ED50 of chlorotrianisene were lowered by 3.9-fold. Chlorotrianisene inhibited the growth of both P388 and P388/ADR cells in a concentration-dependent manner [1].
In vivo: Chlorotrianisene markedly varied in its ability to elicit agonist responses on the three measures. On uterine weight and anterior pituitary prolactin, chlorotrianisene behaved as partial agonists. Chlorotrianisene also exhibited strikingly less agonist activity on glandular kallikrein than on PRL or the uterus. Further, the small agonist activity of chlorotrianisene on glandular kallikrein induction differed from that on the uterus or prolactin [2].
Clinical trial: Chlorotrianisene is a estrogen which is highly effective in the suppression of postpartum lactation when given orally in dosage of 48 mg/day for seven days. Recurrence of symptoms and appearance of withdrawal bleeding are virtually eliminated, probably because of the storage of chlorotrianisene in the body fat and its gradual release after cessation of therapy [3].
Reference:
[1] Ramu A, Glaubiger D, Fuks Z. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res. 1984 Oct;44(10):4392-5.
[2] Powers CA, Hatala MA, Pagano PJ. Differential responses of pituitary kallikrein and prolactin to tamoxifen and chlorotrianisene. Mol Cell Endocrinol. 1989 Sep;66(1):93-100.
[3] NULSEN RO, CARMON WB, HENDRICK HO. TACE (chlorotrianisene), a new estrogen for inhibition of lactation. Am J Obstet Gynecol. 1953 May;65(5):1048-51.
| Cas No. | 569-57-3 | SDF | |
| 别名 | 氯丁烯二烯 | ||
| 化学名 | 4,4',4''-(2-chloroethene-1,1,2-triyl)tris(methoxybenzene) | ||
| Canonical SMILES | COC1=CC=C(/C(C2=CC=C(OC)C=C2)=C(Cl)/C3=CC=C(OC)C=C3)C=C1 | ||
| 分子式 | C23H21ClO3 | 分子量 | 380.86 |
| 溶解度 | ≥ 16.1mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6256 mL | 13.1282 mL | 26.2564 mL |
| 5 mM | 0.5251 mL | 2.6256 mL | 5.2513 mL |
| 10 mM | 0.2626 mL | 1.3128 mL | 2.6256 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。